Eyelid ptosis and muscle weakness in a child with Kawasaki disease: a case report

Yao Lin1, Lijun Wang1, Aijie Li1

  • 1Department of Pediatric Cardiology, Children's Hospital, Capital Institute of Pediatrics, No. 2 Yabao Road, Chaoyang District, Beijing, 100020, China.

BMC Pediatrics
|November 28, 2021
PubMed

Insights

Kawasaki disease (KD) can cause rare neurological symptoms like ptosis and muscle weakness in children. Prompt treatment with IVIG, aspirin, and corticosteroids can effectively resolve these KD-related neuromuscular complications.

Area of Science:

  • Pediatric Rheumatology
  • Neurology
  • Vascular Biology

Background:

  • Kawasaki disease (KD) is a critical pediatric illness characterized by acute febrile vasculitis, primarily affecting children under five.
  • Neuromuscular complications, such as ptosis and muscle weakness, are infrequently documented in KD cases.

Observation:

  • A 3-year-old boy diagnosed with KD presented with significant ptosis and muscle weakness (grade IV upper limb, grade III lower limb).
  • Initial investigations revealed hypokalemia (2.62 mmol/L), which normalized with potassium supplementation.
  • Despite correction of hypokalemia, ptosis and muscle weakness persisted, necessitating further neurological workup including MRI and EMG, which ruled out primary neural or muscular disorders.

Findings:

  • The patient received standard KD treatment: intravenous immunoglobulin (IVIG), aspirin, and adjunctive methylprednisolone.
  • Neuromuscular symptoms showed a delayed but complete resolution: ptosis resolved by day 6, and muscle strength, tone, and ambulation normalized by day 14.
  • This suggests a potential direct or indirect impact of KD on neuromuscular function, responsive to anti-inflammatory therapy.

Implications:

  • Kawasaki disease may manifest with neurological and muscular system involvement, including ptosis and weakness.
  • The successful treatment outcome highlights the efficacy of standard anti-inflammatory protocols, including corticosteroids, for managing these rare KD complications.
  • Increased awareness and diagnostic vigilance for neuromuscular involvement in pediatric KD cases are warranted.
Abstract

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...